South Korea Dry Age-Related Macular Degeneration (AMD) Market Size, Share, and COVID-19 Impact Analysis, By Stage (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration), By Age Group (Above 75 Years, Above 60 Years, above 40 Years), and South Korea Dry Age-Related Macular Degeneration (AMD) Market Insights, Industry Trend, Forecasts to 2035

South Korea Dry Age-Related Macular Degeneration (AMD) Market Insights Forecasts to 2035

• The South Korea Dry Age-Related Macular Degeneration (AMD) Market Size was Estimated at USD 130.0 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 9.42% from 2025 to 2035
• The South Korea Dry Age-Related Macular Degeneration (AMD) Market Size is Expected to Reach USD 350.0 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the South Korea Dry Age-Related Macular Degeneration (AMD) Market Size is Anticipated to Reach USD 350.0 Million by 2035, Growing at a CAGR of 9.42% from 2025 to 2035. Increased investment in non-invasive treatments like peptide-based eye drops and growing awareness of retinal health. Developments in AI-powered diagnostics and government-led screening initiatives also support the adoption of early detection and treatment.

Market Overview

The dry age-related macular degeneration (AMD) market in South Korea is the area of the pharmaceutical and healthcare sectors dedicated to the diagnosis, treatment, and management of dry AMD, a chronic eye disease that gradually impairs central vision from retinal degeneration. Additionally, government campaigns to raise awareness of eye health issues and developments in diagnostic technology are two more important factors driving this industry's expansion. The Ministry of Health and Welfare's numerous public health campaigns, which aim to inform the public about the significance of early detection and management of AMD, demonstrate this focus on healthcare. Furthermore, South Korea is investing more in R&D due to innovative therapy fields like gene therapy and new pharmacological approaches, which opens up business opportunities for international markets. Furthermore, the emphasis on pharmaceutical and biotechnological innovation offers a window of opportunity for up-and-coming businesses to look for partnerships with big businesses in order to speed up the development and promotion of their goods. Moreover, as South Korea makes more investments in healthcare technology, there is a chance to improve patient outcomes and telemedicine monitoring and management of AMD. Further, there has been a recent trend of increased cooperation between healthcare providers and educational institutions to support research efforts aimed at treating AMD.

Report Coverage

This research report categorizes the market for the South Korea dry age-related macular degeneration (AMD) market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea dry age-related macular degeneration (AMD) market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea dry age-related macular degeneration (AMD) market.

Driving Factors

The South Korean Dry Age-Related Macular Degeneration (AMD) Market Industry has been driven by technological developments in medical science. Patients now have more treatment options thanks to the development of novel therapies and pharmaceutical interventions. In order to improve treatment efficacy, new medications that target AMD have been registered and are undergoing clinical trials, according to reports from the Ministry of Food and Drug Safety. Additionally, biotechnology companies developing AMD treatments have received support from the South Korean government, which boosts research expenditures in the field. In addition to fostering market expansion, this innovation boom improves the lives of AMD patients.

Restraining Factors

Many elderly consumers ignore early signs of dry AMD due to a lack of public awareness, which delays diagnosis and treatment. When vision changes are mistaken for normal aging, prompt action is hindered, allowing the disease to worsen before an effective treatment is sought.

Market Segmentation

The South Korea dry age-related macular degeneration (AMD) market share is classified into stage and age group.

• The late-stage age-related macular degeneration segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea dry age-related macular degeneration (AMD) market is segmented by stage into early age-related macular degeneration, intermediate age-related macular degeneration, and late age-related macular degeneration. Among these, the late-stage age-related macular degeneration segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Growth in this market has been fueled by rising demand for cutting-edge treatments and higher diagnosis rates. Preventive care is focusing more on the early and intermediate stages, while treatment-focused strategies continue to emphasize the late stage.

• The above 75 years segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea dry age-related macular degeneration (AMD) market is segmented by above 75 years, above 60 years, and above 40 years. Among these, the above 75 years segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Demand for non-invasive therapies and cutting-edge treatments is driven by this market. The 75+ demographic continue to be the main target of clinical and commercial strategies, despite an increase in cases in the over-60 group.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea dry age-related macular degeneration (AMD) market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Korea Institute of Science and Technology
• Samsung Bioepis
• Hanmi Pharmaceutical
• Daewoong Pharmaceutical
• Korea Drug Development Fund
• Others

Recent Developments:

• In December 2024, Korean scientists developed a revolutionary eye drop treatment for dry age-related macular degeneration (AMD), potentially eliminating the need for regular eye injections that millions of elderly patients previously endured.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea Dry Age-Related Macular Degeneration (AMD) Market based on the below-mentioned segments:

South Korea Dry Age-Related Macular Degeneration (AMD) Market, By Stage

• early age-related macular degeneration
• intermediate age-related macular degeneration
• late age-related macular degeneration

South Korea Dry Age-Related Macular Degeneration (AMD) Market, Age Group

• above 75 years
• above 60 years
• above 40 years